The synthesis of dihydroxybenzoperimidine derivatives, which are chromophore-modified
dihydroxyanthracenediones with an additional pyrimidine ring incorporated into the chromophore, is reported. These derivatives are structurally related to the antitumor agent
mitoxantrone. Their synthesis was carried out by the reaction of 6-amino-8,11-dihydroxy-7H-benzo[e]perimidin-7-one (5) or 6,8,11-trihydroxy-7H-benzo[e]perimidin-7-one (10) with a number
of respective (alkylamino)alkylamines. The dihydroxybenzoperimidine derivatives exhibited
in vitro cytotoxic activity against murine leukemia L1210 and human leukemia HL60 cell lines
comparable to that of mitoxantrone. These compounds also exhibited a range of in vitro activity
against the human MDR-type resistant leukemia K562R cell line with the MDR phenotype.
The most active compound of this series, namely 6a, exhibited potent in vitro cytotoxic activity
against a panel of human cell lines. Furthermore, in contrast to both mitoxantrone and
doxorubicin, it displayed little cross-resistance in cell lines characterized by a MDR phenotype.
Cell cycle analysis in the sensitive HT-29 and mitoxantrone-resistant HT-29/Mx (not identified
resistance mechanism) cell lines has revealed that both mitoxantrone and 6a induce a G2/M
block. However, while the proportion of apoptotic cells after mitoxantrone treatment is similar
for both sensitive and resistant cell lines, it is much lower for 6a. Compound 6a tested against
P388 murine leukemia in vivo displayed a significant antitumor effect (%T/C 196 at an optimal
dose of 10 mg/kg). The property of overcoming the cross-resistance was maintained also in in
vivo efficacy studies, where no difference was observed in the antitumor activity of compound
6a against the A2780 human tumor xenograft and its MDR A2780/Dx subline. We conclude
that benzoperimidines, if properly substituted, constitute a novel class of compounds that can
overcome multidrug resistance.